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Abstract: Parkinson’s disease (PD) is the second most common neurodegenerative disorder, and is
characterized by a progressive degeneration of the dopaminergic neurons in the substantia nigra.
Although not completely understood, several abnormal cellular events are known to be related with
PD progression, such as oxidative stress, mitochondrial dysfunction and apoptosis. Accordingly,
the aim of this study was to evaluate the neuroprotective effects of Codium tomentosum enriched
fractions in a neurotoxicity model mediated by 6-hydroxydopamine (6-OHDA) on SH-SY5Y human
cells, and the disclosure of their mechanisms of action. Additionally, a preliminary chemical screening
of the most promising bioactive fractions of C. tomentosum was carried out by GC-MS analysis. Among
the tested fractions, four samples exhibited the capacity to revert the neurotoxicity induced by 6-OHDA
to values higher or similar to the vitamin E (90.11 ± 3.74% of viable cells). The neuroprotective
effects were mediated by the mitigation of reactive oxygen species (ROS) generation, mitochondrial
dysfunctions and DNA damage, together with the reduction of Caspase-3 activity. Compounds
belonging to different chemical classes, such as terpenes, alcohols, carboxylic acids, aldehydes, esters,
ketones, saturated and unsaturated hydrocarbons were tentatively identified by GC-MS. The results
show that C. tomentosum is a relevant source of neuroprotective agents, with particular interest for
preventive therapeutics.
Keywords: seaweed; marine natural products; neurodegenerative disease; SH-SY5Y cells; oxidative
stress; mitochondrial dysfunction
1. Introduction
Neurodegenerative diseases are estimated to surpass cancer as the second most common cause
of death among the elderly [1]. For this reason, in recent years there has been a great deal of interest
in the search for new, safer, and effective neuroprotective agents that can be used in the therapy of
neurodegenerative diseases such as Parkinson’s disease (PD) [1,2]. PD is one of the most impactful
human diseases without an effective cure, making imperative the research on innovative therapeutics [3].
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Worldwide, there is a growing interest in the development of more selective and effective therapeutic
agents to prevent or to delay the progression of neurodegeneration [4].
PD involves the loss or degeneration of dopaminergic neurons in the substantia nigra pars compacta
(SNpc) and the accumulation of Lewy bodies, and abnormal intracellular aggregates containing proteins
such as alpha-synuclein, sinfilin-1 and ubiquitin [5]. The etiology of PD remains largely unknown [6];
however, it is assumed that the main mechanisms involved in the development and progression
of this disease are associated with oxidative stress, mitochondrial dysfunction, neuroinflammation,
and apoptosis, among others, which act together leading to degeneration of dopaminergic neurons [7].
Natural products obtained from marine organisms have been shown to be a potential source of
novel therapeutic agents. Among these organisms, macroalgae have been reported for their ability
to produce relevant bioactive compounds [8], mainly derived from their secondary metabolism
as a defense response to environmental variations [2]. These metabolites are known to exhibit a
broad range of bioactive properties such as antioxidant [9], antimicrobial [10], anti-inflammatory [11],
anti-tumoral [12], and neuroprotective [13]. Thus, these metabolites can inspire the development of
new drugs for the therapy of various pathologies, such as cancer, diabetes, and neurodegenerative
diseases [2]. Concerning neurodegenerative disorders, the benefits of seaweed-derived components
on the prevention and/or treatment of neurodegeneration were previously reported [14]. Recently,
Souza and co-workers [15] reported the neuroprotective activity of kappa-carrageenan isolated from
the seaweed Hypnea musciformis on 6-hydroxydopamine (6-OHDA)-induced neurotoxicity on SH-SY5Y
cells by modulation of the mitochondrial membrane potential and the decrease of Caspase-3 activity.
Wen and co-workers [16] showed that the compound austrasulfone isolated from the marine soft coral
Cladiella australis has potent neuroprotective effects against the 6-OHDA-induced neurotoxicity on the
neuroblastoma SH-SY5Y cell line, as well as anti-inflammatory activity on RAW 264.7 macrophage
cells. Additionally, studies carried out by Gao and co-workers [17] demonstrated the neuroprotective
effect of the sulfated polysaccharide fucoidan on PC12 cells by blocking the H2O2-induced apoptosis,
scavenging ROS formation and reducing lactate dehydrogenase activity. The authors verified that
this fucoidan protected the neurocytes against H2O2-induced apoptosis via reducing ROS levels and
activating PI3K/Akt signaling pathway.
In the present work, the green macroalgae C. tomentosum, found in the intertidal zone of the
Portuguese coast [18] was evaluated for its ability to produce neuroprotective substances. The number
of studies focusing on the biological potential of this species is limited, since only one report has
revealed the antioxidant, anti-genotoxic, anti-tumorigenic and hypoglycemic potential of crude
ethanolic extracts [18]. On the other hand, Silva and co-workers [13] demonstrated the neuroprotective
capacity of C. tomentosum methanol and dichloromethane crude extracts, highlighting the need to
pursue the investigation focused on the therapeutic potential of this species. Thus, the present work is
aimed at the fractionation and identification of the bioactive molecules produced by C. tomentosum,
the evaluation of their antioxidant activity, and the understanding of the mechanisms behind their
neuroprotective effects.
2. Results
2.1. Yields, Total Phenolic Content and Antioxidant Activity of Codium tomentosum Fractions
Freeze-dried samples of green seaweed C. tomentosum were sequentially extracted overnight with
methanol (MeOH) and dichloromethane (DCM) (in a biomass/solvent ratio of 1:40) with constant
stirring at room temperature. The resulting solutions were filtrated, and the organic phases were
evaporated in a rotary evaporator (IKA HB10), at 30 ◦C. Each crude extract was fractionated by
vacuum liquid chromatography (VLC) affording a total of 14 fractions (MF1-7 and DF1-7, respectively).
An overview of extraction and fractionation sequences is depicted in Figure 1.
The amounts of phenolic compounds and the antioxidant activity of all these fractions
were evaluated.
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Figure 1. Extraction and fractionation flowchart of the green seaweed Codium tomentosum.
The fractionation yields, the total phenolic content (TPC), and antioxidant capacity assessed
through 2,2-diphenyl-1-picrylhydrazyl radical (DPPH) scavenging activity, oxygen radical absorbance
capacity (ORAC), and ferric reducing antioxidant power (FRAP) assays of the different fractions
obtained from the green seaweed C. tomentosum are summarized in Table 1.
Table 1. Fractionation yields, TPC, and antioxidant capacity of Codium tomentosum fractions.
Crude Extract Fraction Yield (%) TPC a DPPH b FRAP c ORAC d
MeOH
MF1 0.09 2.24 ± 0.15 >100 282.87 ± 14.27 99.91 ± 0.57
MF2 3.29 3.96 ± 0.26 >100 288.40 ± 11.42 28.92 ± 0.51
MF3 0.88 2.58 ± 0.13 >100 282.99 ± 2.51 52.60 ± 1.28
MF4 0.57 7.30 ± 0.47 >100 271.33 ± 7.34 74.76 ± 0.48
MF5 0.65 4.32 ± 0.30 >100 273.01 ± 1.81 66.32 ± 0.95
MF6 6.73 4.38 ± 0.12 >100 292.73 ± 3.73 72.73 ± 1.36
MF7 16.89 2.47 ± 0.05 >100 23.79 ± 8.45 98.55 ± 2.28
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Table 1. Cont.
Crude Extract Fraction Yield (%) TPC a DPPH b FRAP c ORAC d
CH2Cl2
DF1 0.58 4.18 ± 0.13 >100 24.40 ± 1.22 38.88 ± 0.73
DF2 1.52 10.43 ± 0.40 >100 67.67 ± 8.05 62.06 ± 1.67
DF3 1.53 5.51 ± 0.75 >100 825.73 ± 32.59 98.84 ± 6.00
DF4 1.00 3.51 ± 0.20 >100 1008.27 ± 18.18 144.15 ± 2.02
DF5 6.35 4.30 ± 0.23 >100 636.21 ± 22.21 94.56 ± 1.02
DF6 13.88 4.57 ± 0.17 >100 356.95 ± 3.73 165.34 ± 6.42
DF7 8.58 5.69 ± 0.16 >100 582.11 ± 20.81 193.85 ± 14.30
BHT - - >100 2821.50 ± 51.27 142.87 ± 8.71
a mg gallic acid equivalents (GAE)/g extract; b radical scavenging activity (EC50 µg/mL); c µM FeSO4/g extract; d µmol
trolox equivalents (TE)/g extract. EC50 values were determined for a 95% confidence interval. MeOH—methanol;
CH2Cl2—dichloromethane.
As shown in Table 1, the highest fractionation yields were achieved through the elution with
methanol (DF6—13.88%; MF6—6.73%), and acetone (MF7—16.90%; DF7—8.58%), while lower yields
were obtained with the less polar solvent cyclohexane (MF1—0.09%; DF1—0.57%).
Regarding the amounts of phenolic compounds, DF2 fraction from dichloromethane crude extract
presented the highest TPC (10.43 ± 0.40 mg GAE/g extract) followed by MF4 fraction from methanolic
crude extract (7.30 ± 0.47 GAE/g extract). On the other hand, MF1 and MF7 fractions presented the
lowest TPC (2.24 ± 0.15 GAE/g extract and 2.47 ± 0.05 GAE/g extract, respectively). Concerning the
antioxidant activities, none of the fractions demonstrated potential to reduce the DPPH radical. In the
ORAC assay, DF7 fraction showed the highest antioxidant activity (193.85 ± 14.30 µmol TE/g extract)
followed by DF6 (165.34 ± 6.42 µmol TE/g extract) and DF4 (144.15 ± 2.02 µmol TE/g extract) fractions,
respectively. MF2 fraction exhibited the lowest capacity to reduce peroxyl radicals (28.92 ± 0.51 µmol
TE/g extract). Fractions DF3 (825.73 ± 32.59 µM FeSO4/g extract), DF4 (1008.27 ± 18.18 µM FeSO4/g
extract) and DF5 (636.21 ± 22.21 µM FeSO4/g extract) revealed the highest efficiency to reduce ferric
ions, while the lowest activity was displayed by DF1 (24.40 ± 1.22 µM FeSO4/g extract).
2.2. Neurotoxicity and Neuroprotective Effects of Codium tomentosum Fractions on SH-SY5Y Cells
The neurotoxic effects of C. tomentosum fractions (100 µg/mL; 24 h) were evaluated on SH-SY5Y
cells. All the non-toxic fractions were then evaluated for their neuroprotective potential on SH-SY5Y
exposed to the neurotoxic effects of 6-OHDA (100 µM). Cell viability was estimated by the MTT assay
and results are presented in Figure 2.
Among all fractions, only three induced a significant reduction of SH-SY5Y cells’ viability
(Figure 2A): MF3 from methanolic crude extract (72.27 ± 3.56% of viable cells); DF6 (38.09 ± 2.41% of
viable cells) and DF7 (60.02 ± 9.66% of viable cells) from DCM crude extract. Thus, the neuroprotective
evaluation was conducted on the remaining non-toxic fractions. The exposition of SH-SY5Y cells to
6-OHDA (100 µM) for 24 h led to a reduction of cell viability of about 42% (58.92 ± 2.49% of viable cells)
when compared to vehicle (100 ± 1.85% of viable cells). However, when SH-SY5Y cells were exposed
to 6-OHDA, in the presence of C. tomentosum fractions (100 µg/mL), four samples exhibited capacity to
revert (30–50%) the neurotoxicity induced by 6-OHDA to values similar to the vitamin E standard
(90.11 ± 3.74% of viable cells) (Figure 2B): MF2 (108.50 ± 4.53% of viable cells); DF1 (104.8% ± 3.85% of
viable cells); DF2 (89.15 ± 2.23% of viable cells); and DF5 (93.19 ± 2.53% of viable cells).
2.3. Neuroprotective Effects of Codium tomentosum Fractions on PD Hallmarks
To investigate whether the neuroprotective effects mediated by C. tomentosum fractions on
SH-SY5Y cells’ viability are associated with PD, several hallmarks were studied, namely oxidative
stress, apoptosis, ROS production, changes in mitochondrial membrane potential, and Caspase-3
activity. The results are depicted in Figure 3.
Molecules 2020, 25, 5478 5 of 14
Figure 2. (A) Neurotoxicity of Codium tomentosum fractions (100 µg/mL, 24 h) and (B) neuroprotective
effects of non-neurotoxic fractions (100 µg/mL, 24 h) in the presence of 6-OHDA (100 µM) on SH-SY5Y
cells. (-) 6-OHDA; Vit E (Vitamin E). The values in each column represent the mean ± standard error of
the mean (SEM) of three or four independent experiments. Symbols represent significant differences
(ANOVA, Dunnett’s test, p < 0.05) when compared to: * vehicle and # 6-OHDA.
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Figure 3. PD hallmarks evaluation on SH-SY5Y cells when exposed to 6-OHDA (100 µM) and Codium
tomentosum fractions (100 µg/mL; 6 h). (A) ROS production; (B) changes in mitochondrial membrane
potential; (C) Caspase-3 activity. (-) 6-OHDA. The values in each column represent the mean ± standard
error of the mean (SEM) of three or four independent experiments. Symbols represent significant
differences (ANOVA, Dunnett’s test, p < 0.05) when compared to: * vehicle and # 6-OHDA.
The exposition of SH-SY5Y cells to 6-OHDA led to a marked increase of ROS levels (203.1± 17.78%)
when compared to vehicle (100.00 ± 3.53%) (Figure 3A). In the presence of C. tomentosum fractions,
all of them induced a significant decrease of the ROS levels being the highest reduction mediated by
DF1 and DF5 fractions (101.58 ± 8.44% and 101.17 ± 4.15%, respectively).
To understand if the neuroprotective effects of C. tomentosum fractions were mediated by biological
events on mitochondria, possible changes on MMP were studied. The exposition of SH-SY5Y cells to
6-OHDA induced a strong depolarization of the MMP (376.40 ± 39.96%) when compared with the
vehicle (100.00± 2.05%) (Figure 3B). On the other hand, the treatment conducted with seaweed fractions
exhibited a preventive effect on MMP against the depolarization induced by 6-OHDA (376.40 ± 39.96%),
with the highest effect being mediated by MF2 (114.90 ± 4.04%) and DF5 fractions (128.60 ± 15.83%).
Caspase-3 activity was determined to understand if the neuroprotective effects of C. tomentosum
fractions were mediated by apoptotic pathways. The exposure of SH-SY5Y cells to 6-OHDA increased
its activity (381.30 ± 57.13%) when compared with the vehicle (100.00 ± 4.83%) (Figure 3C). On the
other hand, the treatment with MF2 (62.70 ± 5.59%), DF2 (107.10 ± 18.77%), and DF5 (74.43 ± 3.55%)
fractions led to a marked decrease in Caspase-3 activity.
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2.4. Chemical Characterization of Codium tomentosum Bioactive Fractions
A preliminary chemical characterization of the most bioactive fractions (MF2, DF1, DF2 and
DF5) of C. tomentosum was performed by GC-MS. The compounds were tentatively identified by
matching their mass spectra with those of reference compounds stored in the GC-MS mass spectral
databases, evidencing the presence of different chemical groups such as terpenes, alcohols, carboxylic
acids, esters, ketones and hydrocarbons. In fraction MF2, the presence of alkenes (1-docosene,
9-eicosene, 1-hexacosene), the fatty alcohol 1-tricosanol, and the glycol 1,2-octodecanediol was verified.
Three alkanes (cyclohexadecane, eicosane, docosane), the heptafluorobutanoic acid and sebacic acid,
bis (2-ethylhexyl) ester, one alcohol (2-hexyl-1-decanol), and one aldehyde (octadecanal) were detected
in fraction DF1. Regarding fraction DF2, besides 2-methylundecanal and pentafluoropropionic
acid, heptadecyl ester, the alcohols 2-hexyl-1-decanol and 1-tricosanol were also identified in this
fraction. Finally, the monoterpenoid lactone loliolide, together with the glycol 1,2-octadecanediol,
and the hexanedioic acid, bis (2-ethylhexyl) ester, were detected in fraction DF5. A terpene ketone
(perhydrofarnesyl acetone) was present in fractions MF2, DF2, and DF5. Although in small amounts,
these last two fractions also evidenced the presence of two peaks with characteristic mass fragmentation
patterns of sterols. Additional data concerning compounds identification are available in Table S1
(Supplementary Information).
3. Discussion
Marine compounds have shown potential as possible therapeutic agents that can slow the
processes associated with neuronal cell loss in neurodegenerative diseases, having ability to act in
distinct biological targets.
Oxidative stress is believed to be one of the main triggers of neurodegenerative diseases,
particularly in PD, and several studies have been carried out to understand the neuroprotective effects
of antioxidant molecules [19]. These molecules have been widely discussed by several researchers as
a possible therapy against neuronal death, as they have the ability to neutralize free radicals. In the
present study, the antioxidant and neuroprotective potential of fractions from the green seaweed
C. tomentosum were evaluated. Regarding their antioxidant capacity, three complementary methods
(DPPH, FRAP, ORAC) were assayed and the results correlated with total phenolic content (TPC).
None of the tested fractions showed significant antioxidant potential, which can be correlated with
their low TPC levels. These results are in accordance with those reported by Pinteus and co-workers [9],
who conducted an antioxidant screening of 27 algae collected from the Peniche coast (Portugal) in
which green algae also did not show a relevant antioxidant capacity, when compared with other red
and brown species. In recent years, the antioxidant potential of seaweeds has been fully documented in
the literature [8,9,19], and has been attributed to the presence of a wide variety of chemical structures
with high antioxidant capacity such as phenols, flavonoids, phlorotannins, sulfated polysaccharides
and ascorbic acid [20].
Several mechanisms are involved in neuroprotection and, although without an expressive
antioxidant ability, C. tomentosum fractions were evaluated for their neuroprotective potential in an
in vitro model of PD. Marine extracts and derived compounds have been previously reported by
several studies to exhibit neuroprotective effects against 6-OHDA neurotoxicity and, consequently,
this model has been widely used to mimic experimental models of PD [8,13,20,21]. In this study,
it is shown that C. tomentosum fractions are able to promote cells recover from the toxicity induced
by 6-OHDA exposition. Our results are consistent with other studies in which C. tomentosum
dichloromethane extracts increased neuronal cells’ viability in 35%, blocking the toxic effects of
6-OHDA [13]. Although the mechanisms responsible for inducing cell death in PD have not been totally
clarified, oxidative stress is clearly involved, due to an increase of ROS, resulting in mitochondrial
impairment, lipid peroxidation, DNA damage, and cell death [21,22].
Producing about 90% of cellular ROS, mitochondria have a major role in oxidative stress related
diseases. In fact, mitochondrial dysfunction has long been implicated in PD pathogenesis [23].
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The production of ROS by inhibition of Complex I is a key mechanism for dopaminergic (DA) neuronal
damage as DA neurons are susceptible to oxidative stress due to dopamine autoxidation. The generation
of ROS also induces the damage of Complex I and III and the oxidation of mitochondrial and cytoplasmic
proteins, leading to their dysfunction [23,24]. Based on the results obtained in the present work, it was
found that DF1, DF2 and DF5 fractions were able to prevent ROS production and mitochondrial
dysfunction promoted by 6-OHDA. These results are in agreement with those previously obtained
with the seaweed Bifurcaria bifurcata [8], in which its dichloromethane fractions prevented cell death,
maintained mitochondrial function and reduced ROS production. Souza et al. [15] also demonstrated,
in the same in vitro model, that kappa-carrageenan from the algae Hypnea musciformis, prevented
mitochondrial potential changes and reduced H2O2 production. Additionally, several authors reported
the neuroprotective properties of seaweed derived polysaccharides on 6-OHDA-induced neurotoxicity
in SH-SY5Y cells [24–26].
Besides oxidative stress and mitochondrial dysfunction, apoptosis has also been implicated in
neuronal death in PD [27]. These mechanisms are mediated by several initiators and executer caspases,
via intrinsic or extrinsic pathways. The initiating caspases (-9 and -8) converge onto a common pathway
of executioner caspases involving Caspase -3 and -6. The activation of executioner caspases leads to
morphological features of apoptosis, such as DNA cleavage and its subsequent fragmentation. Based
on the results presented here, it was verified that fractions MF2, DF2, and DF5 prevented the increase
of Caspase -3 activity promoted by 6-OHDA.
A preliminary chemical screening of C. tomentosum most promising bioactive fractions was carried
out by GC-MS analysis, and several compounds belonging to different chemical classes were identified,
e.g., terpenes, fatty alcohols, carboxylic acids, aldehydes, esters, ketones, saturated and unsaturated
hydrocarbons. Accordingly, Valentão et al. [18] also detected compounds belonging to some of the
above described chemical classes in C. tomentosum, collected at Espinho coast (Portugal). The GC-MS
analysis of other Codium species, like C. bursa, also suggested the presence of components belonging to
the above described structural groups [26]. Numerous constituents from natural resources, namely
those of marine origin having different structural features are reported for their neuroprotective
properties [28–31]. Among the less polar compounds, there is great evidence that lipids play a central
role in PD [32]; however, current data are still too preliminary, and more detailed studies about this issue
are needed. Nevertheless, given the lipidic richness of C. tomentosum [18,33–35], the hypothesis that
lipidic and other less polar constituents, including sterols [36], can be involved in the neuroprotection
must not be discarded. As reported by Zhang et al. [37] the lipophilicity enhances the blood-brain
barrier (BBB) penetration ability, even though BBB penetration is a highly complex process and a result
of many cooperative effects. Effectively, one of the main bottlenecks associated with the development
of new therapeutics for PD is the difficulty of many drugs to reach the brain, due to this highly selective
semi-permeant barrier that protects brain and the spinal cord from many foreign substances. It is
critical the development of deeper investigation studies in more complex in vitro models, such as
co-cultures, to understand the ability of C. tomentosum-derived compounds to cross the BBB, and the
possibility of their incorporation in smart delivery systems such as nanoparticles for brain drug delivery,
tissue engineering, and new biomaterials [38]. This strategy will contribute to refine the selection of
the most active compounds with neuroprotective potential suppressing the gap between in vitro and
in vivo assays.
In conclusion, the current lack of studies on seaweed-derived neuroprotective agents evidences
the relevance of C. tomentosum as a source of new compounds with potential neuroprotective properties,
opening new research lines. This work showed that its bioactive fractions markedly inhibited
6-OHDA neurotoxicity induced in human neuroblastoma SH-SY5Y cells. Our results suggest that
the neuroprotective effects are mediated by the mitigation of ROS generation and mitochondrial
dysfunctions, together with the reduction of Caspase-3 activity. To the best of our knowledge, this is
the first study focusing on the neuroprotective capacity of C. tomentosum in the in vitro PD model
here described. Work is ongoing regarding the isolation and chemical characterization of promising
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constituents from the most bioactive fractions as well as compounds’ bioavailability studies on in vitro
models that mimic the BBB. Nevertheless, the possibility of synergistic effects between the identified
constituents need to be considered and can be regarded as an advantage, since Codium spp. is an edible
seaweed that can be explored for nutraceutical and prophylactic purposes to overcome PD impairments.
4. Materials and Methods
4.1. Collection and Preparation of Codium tomentosum Samples
The green seaweed Codium tomentum Stackouse, 1797 was collected in October 2016 at Peniche
coast, Portugal (39◦37′05′′ N, −9◦38′58′′ O), and transported to MARE-Polytechnic of Leiria lab
facilities. The seaweed was rinsed carefully with seawater and distilled water to remove epiphytes,
sand and debris. Then, it was freeze-dried (Scanvac Cool Safe, LaboGene, Lynge, Denmark), ground,
and stored in a cool place protected from light, until further use.
4.2. Seaweed Extraction and Fractionation
Freeze-dried samples of C. tomentosum (445 g) were sequentially extracted with methanol (MeOH)
and dichloromethane (DCM) (VWR-BDH Chemicals, Fontenay-sous-Bois, France) (in a biomass/solvent
ratio of 1:40) with constant stirring, overnight. Crude dried extracts were obtained using a rotary
evaporator (IKA HB10, Staufen, Germany) and/or a speed vacuum equipment (Concentrator Plus,
Eppendorf, Spain). The MeOH (112.64 g, 25.31%) and DCM (6.47 g, 1.45%) crude extracts were
subjected to a normal phase vacuum liquid chromatography (VLC) on silica gel 60 (0.06–0.2 mm, VWR,
Leuven, Belgium). Elution was performed by using cyclohexane with increasing amounts of ethyl
acetate (v/v) as the mobile phase: 1:0 (MF1, 0.02 g; DF1, 0.06 g), 2:1 (MF2, 0.66 g; DF2, 0.16 g), 2:2 (MF3,
0.18 g; DF3, 0.15 g) 1:2 (MF4, 0.11 g; DF4, 0.10 g) 0:1 (MF5, 0.13 g; DF5, 0.63 g), MeOH (MF6,1.35 g; DF6,
1.39 g), and acetone (MF7, 3.38 g; DF7 0.86 g), 400 mL of each eluent (Figure 1). Fractionation yields were
determined in relation to biomass of freeze-dried seaweed. The fractions attained were subjected to a
series of in vitro biological assays, in order to evaluate their antioxidant and neuroprotective potential.
4.3. Quantification of Total Phenolic Content (TPC)
The TPC of C. tomentosum fractions was determined using the Folin–Ciocalteu reagent (Sigma,
Saint Louis, MO, USA) according to the method described by Singleton et al. [39] with slight
modifications [8]. After 1 h of reaction in the dark, the absorbance was measured at 755 nm (Synergy
H1 Multi-Mode Microplate Reader, BioTek® Instruments, Winooski, VT, USA). Gallic acid was used
as standard and TPC is expressed as milligrams of gallic acid equivalents per gram of dry extract
(mg GAE/g of extract).
4.4. Evaluation of Antioxidant Activity
4.4.1. 2-Diphenyl-1-picrylhydrazyl (DPPH) Radical Scavenging Activity
The ability of C. tomentosum fractions to scavenge the DPPH radical was determined according
to the protocol described by Pinteus et al. [9]. Briefly, the reaction mixtures were incubated in the
dark, for 30 min, at room temperature. The absorbance was then measured at 517 nm. The samples
were tested at a maximum concentration of 100 µg/mL. A dose-response analysis (10–100 µg/mL) was
performed for the samples with DPPH reduction >50% for EC50 determination.
4.4.2. Oxygen Radical Absorbance Capacity (ORAC-Fluorescein)
The ability of seaweed fractions to neutralize peroxyl free radicals avoiding fluorescein oxidation
was accomplished according to the protocol described by Dávalos et al. [40]. Samples (20 µL),
and fluorescein (120 µL; 70 nM, final concentration) were added to a 96-well microplate and
pre-incubated for 15 min at 37 ◦C. Ending this time, AAPH (2,2′-Azobis(2-methylpropionamidine)
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dihydrochloride (Sigma-Aldrich, Barcelona, Spain) solution (60 µL; 12 mM, final concentration) was
added quickly. The microplate was immediately placed in the reader and the fluorescence (λ excitation:
458 nm; λ emission: 520 nm) recorded every minute, for 240 min. Trolox (Sigma-Aldrich, St. Louis, MO,
USA) was used as an antioxidant standard. The results are expressed in µmol of Trolox equivalents/g
of dry extract (µmol TE/g of extract).
4.4.3. Ferric Reducing Antioxidant Power (FRAP)
The capacity of seaweed fractions to reduce F3+ to F2+ through electron donation was performed
according to Benzie and Strain [41] with slight modifications [8]. FRAP reagent was prepared freshly
with 0.3 M acetate buffer (pH = 3.6), 10 mM of 2,4,6-tri(2-pyridyl)-s-triazine, (TPTZ) (Alfa Aesar,
Kandel, Germany) in 40 mM HCl and 20 mM ferric solution using FeCl3 (10:1:1) and pre-heated at
37 ◦C. Briefly, 2 µL of C. tomentosum samples were added to 198 µL of FRAP reagent and incubated
at 37 ◦C in the dark for 30 min. FeSO4 was used as standard, and the absorbance was then read at
593 nm. The difference between the absorbance of test fractions and the blank reading was calculated,
and results expressed as µM of FeSO4/g of extract (µM FeSO4/g of extract).
4.5. Evaluation of the Neuroprotective Potential of Codium tomentosum
4.5.1. Cell Culture Maintenance Conditions
The biological activities of fractions were conducted on an in vitro cellular model of human
neuroblastoma (SH-SY5Y cells, strain number ACC 209) previously acquired from DSMZ (Deutsche
Sammlung von Mikroorganismen und Zellkulturen GmbH) biobank. The cells were cultured according
to the supplier’s instructions. SH-SY5Y cells grew in DMEM:F12 medium (Biowest, Riverside, MO,
USA) supplemented with 10% (v/v) fetal bovine serum (Biowest, Riverside, MO, USA) and 1% of
antibiotic mixture constituted by 1% penicillin/streptomycin (Sigma, Rehovot, Israel). SH-SY5Y cells
were maintained in a humidified atmosphere with 5% CO2 at 37 ◦C.
4.5.2. Neurotoxic and Neuroprotective Potential
The neurotoxicity was evaluated on SH-SY5Y cells at 75–85% of total confluence. Cells were
treated with seaweed fractions (100 µg/mL) for 24 h to determine and select the non-neurotoxic
samples/concentrations for the next assays. Regarding the neuroprotective assay, SH-SY5Y cells were
exposed to 6-OHDA (100 µM) (Sigma, St. Louis, MO, USA) in the presence/absence of non-neurotoxic
seaweed fractions (100 µg/mL). The effects on SH-SY5Y cells’ viability was then estimated by the MTT
(3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) assay (VWR, Solon, OH, USA).
Cells were incubated with MTT (1.2 mM) for 1 h at 37 ◦C. Ending this time, 100 µL of dimethyl sulfoxide
(DMSO) were added, and the absorbance read at 570 nm (Synergy H1 Multi-Mode Microplate Reader,
BioTek® Instruments, Winooski, VT, USA). The results were expressed as percentage of the control.
4.5.3. Neuroprotective Effects on PD Biomarkers
Determination of Intracellular Reactive Oxygen Species (ROS) Levels
The ROS levels were determined using the oxidation sensitive fluoroprobe 5(6)-carboxy-2′,7′-
dichlorofluorescein diacetate (carboxy-H2DCFDA) (Invitrogen, Bleiswijk, Netherlands) according to
Ouazia et al. [42] with slight modifications. Briefly, SH-SY5Y cells were exposed to 6-OHDA (100 µM) in
the presence/absence of seaweed fractions (100 µg/mL) for 6 h. Cells were then washed with phosphate
buffered saline (PBS) and incubated with carboxy-H2DCFDA (20 µM) probe, previously dissolved in
serum-free medium for 1 h at 37 ◦C. Ending this time, the fluorescence was read (λ excitation: 527 nm;
λ emission: 495 nm).
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Mitochondrial Membrane Potential (MMP)
Analysis of MMP was performed using the JC-1 fluorescent dye (Molecular Probes, Eugene,
OR, USA) according to Silva et al. [8]. SH-SY5 cells were exposed to 6-OHDA (100 µM) in the
presence/absence of seaweed fractions (100 µg/mL) for 6 h. Cells were then washed with PBS and
incubated with JC-1 solution (3 µM) in the dark, for 15 min, at 37 ◦C. After this time, the JC-1 dye was
removed, and PBS was added to wells. The fluorescence was read at 530 nm (monomers) and at 590 nm
(aggregates) and 490 nm emission/excitation wavelengths, respectively. The results were calculated
from the ratio between JC-1 monomers and aggregates and are expressed in percentage of control.
Caspase-3 Activity
Caspase-3 activity was evaluated using the caspase-3 fluorometric assay kit (CASP3F-KIT, Sigma,
St. Louis, MO, USA) according to the manufacturers´ instructions. Briefly, SH-SY5Y cells were treated
with 6-OHDA (100 µM) in the presence/absence of seaweed fractions (100 µg/mL) for 6 h. Ending
treatment time, cells were washed with PBS, harvested, and enzyme activity determined by reading
the fluorescence at 360 nm and 460 nm emission and excitation wavelengths, respectively. The results
were calculated from the slope of the curve and are expressed in percentage of control.
4.6. Chemical Characterization of Codium tomentosum Bioactive Samples
Gas Chromatography-Mass Spectrometry (GC-MS) Analysis
GC–MS qualitative analysis was performed in a Shimadzu QP2010-Plus GC/MS system equipped
with a TRB5MS (30 m × 0.25 mm i.d. × 0.25 µm film thickness) capillary column (Teknokroma,
Barcelona, Spain) operating in the linear velocity mode. The carrier gas was helium 5.0 (Linde,
Lisboa, Portugal), with a constant flow of 1 mL/min. Samples were dissolved in dichloromethane
and automatically injected. Injections were performed in split mode, with a ratio of 1/9. The injector
port was heated to 280 ◦C. The initial column temperature of 60 ◦C was held for 2 min, followed
by a temperature ramp of 30 ◦C/min to 300 ◦C held for 15 min. All mass spectra were acquired
in electron impact (EI) mode at 70 eV. The operate temperatures were 200 ◦C for MS ion source,
and 250 ◦C for the liner interface. Analysis were performed in full scan mode with mass ranging from
10 to 800 m/z. Compounds were identified by matching the mass fragmentation patterns with those
stored in the GC-MS mass spectral databases (Wiley 229 and NIST-National Institute of Standards and
Technology libraries).
4.7. Data and Statistical Analysis
When applicable, results are presented as mean ± standard error of the mean (SEM).
The determination of EC50 was attained from sigmoidal dose–response variable-slope curves using the
GraphPad Prism v.8 software (GraphPad Software Inc., San Diego, CA, USA). One-way analysis of
variance (ANOVA) with Dunnett’s multiple comparison of group means was employed to determine
significant differences relatively to the control treatment. All other post hoc analyses were conducted
using Tukey’s test. All data were checked for normality and homoscedasticity. Comparisons
concerning variables, which did not meet variance or distributional assumptions, were carried out
with Kruskal–Wallis non-parametric tests. At least three independent experiments were carried out
in triplicate.
Supplementary Materials: The following are available online, Table S1: Identification of compounds in Codium
tomentosum bioactive fractions by GC-MS.
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